Effect of PMX-DHP for sepsis due to ESBL-producing E. coli in an extremely low-birthweight infant

Naoto Nishizaki, Mayu Nakagawa, Satoshi Hara, Hisayuki Oda, Masato Kantake, Kaoru Obinata, Yuki Uehara, Keiichi Hiramatsu, Toshiaki Shimizu

研究成果: ジャーナルへの寄稿学術論文査読

19 被引用数 (Scopus)

抄録

We report a case of early onset sepsis caused by (CTX for cefotaximase and M for Munich)-type extended-spectrum β-lactamase-producing Escherichia coli (ESBL E. coli) in a preterm infant weighing 601 g. He was given meropenem and treated for endotoxin absorption with polymyxin B-immobilized fibers with only 8 mL of priming volume. The patient survived without any short-term neurological or respiratory sequelae. The choice of antibiotics is particularly important in seriously ill neonates with sepsis due to ESBL-producing organisms. Polymyxin B hemoperfusion might be an innovative therapy for severe neonatal sepsis and could improve outcome even in an extremely low-birthweight infant.

本文言語英語
ページ(範囲)411-414
ページ数4
ジャーナルPediatrics International
58
5
DOI
出版ステータス出版済み - 01-05-2016
外部発表はい

All Science Journal Classification (ASJC) codes

  • 小児科学、周産期医学および子どもの健康

フィンガープリント

「Effect of PMX-DHP for sepsis due to ESBL-producing E. coli in an extremely low-birthweight infant」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル